Pari Respiratory

Pari is a manufacturer and innovator for Reusable Nebulizers. With a host of more clinical trails than any other brand, Pari continues to be the leader in reusable nebulizers in the industry. Two of Pari's flagship nebulizers, the Pari LC Sprint and Pari LC Plus have consistently provides respiratory patients with particle size nebulizer treatments that are fast and targeted. Pari’s innovations seek to improve the quality of life for respiratory patients of all ages. While Pari continues to research new nebulizer devices, Pari also focuses on patient safety and efficient delivery of aerosol to the lungs. Pari works alongside many pharmaceutical companies to ensure that a Pari Nebulizer will efficiently disperse patient medications. In fact, many of top pharmaceutical companies list the Pari Nebulizers in their medication product inserts. Trusted globally for quality and innovation, Pari provides superior nebulizer performance.

Pari Reusable Nebulizers

Pari nebulizers were used in the following clinical trials to test safety and efficacy:

• Pulmozyme® (Genentech) for cystic fibrosis.
• Pulmicort Respules® (AstraZeneca) for asthma.
• TOBI® (Novartis) for cystic fibrosis.
• DuoNeb® (Dey) for COPD and asthma.
• AccuNeb® (Dey) for asthma.
• Perforomist® (Dey) for COPD.
• Xopenex® (Sunovion) for asthma.
• Brovana™ (arfomoterol tartate) (Sunovion) for COPD.
• Cayston® (Aztreonam lysine) (Gilead) for cystic fibrosis.
• Denufosol tetrasodium (Inspire) for cystic fibrosis.

Nebulizer Studies

• Home Nebulizer Treatment Study – survey of patients with chronic lung disease.
• Nebulizer COPD Treatment Study – quality of life improvements for COPD patients.
• Pari LC Sprint Jet Nebulizer Study – assessment of effectiveness on different age groups.
• Pari White Paper on Portable Jet Nebulizers – comparative testing results for portable nebulizers.